Focused On-demand Library for Ubiquitin carboxyl-terminal hydrolase 10

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
Q14694

UPID:
UBP10_HUMAN

ALTERNATIVE NAMES:
Deubiquitinating enzyme 10; Ubiquitin thioesterase 10; Ubiquitin-specific-processing protease 10

ALTERNATIVE UPACC:
Q14694; B2RDJ8; B4DS84; Q9BWG7; Q9NSL7

BACKGROUND:
Deubiquitinating enzyme 10, known as USP10, is integral to cellular homeostasis, impacting DNA damage response and autophagy through its action on p53/TP53 and BECN1. It negates the ubiquitination of critical ribosomal proteins and CFTR, facilitating their recycling and function. Additionally, USP10 modulates NF-kappa-B activation, playing a role in inflammatory responses.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Deubiquitinating enzyme 10 reveals its potential in developing treatments for cancer, cystic fibrosis, and autoimmune diseases. Its regulatory effect on p53/TP53 and involvement in autophagy and inflammation positions it as a promising therapeutic target.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.